Competitive fitness of influenza B viruses with neuraminidase inhibitor-resistant substitutions in a coinfection model of the human airway epithelium

Journal of Virology

Volumn 89, Issue 8, 2015, Pages 4575-4587

  Burnham, Andrew J ^a,c   Armstrong, Jianling ^a   Lowen, Anice C ^b   Webster, Robert G ^a   Govorkova, Elena A ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Gryphon Scientific   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR; ENZYME INHIBITOR; PRIMER DNA; SIALIDASE;

ANIMAL CELL; ANTIVIRAL RESISTANCE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC50; INFLUENZA VIRUS B; MIXED INFECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; VIROGENESIS; VIRUS LOAD; VIRUS PARTICLE; VIRUS RELEASE; VIRUS REPLICATION; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; DOG; GENETICS; HIGH THROUGHPUT SEQUENCING; INFLUENZA B VIRUS; KINETICS; MDCK CELL LINE; METABOLISM; MISSENSE MUTATION; PATHOGENICITY; PHYSIOLOGY; REPRODUCTIVE FITNESS; RESPIRATORY TRACT MUCOSA; REVERSE GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

CERCOPITHECINE HERPESVIRUS 1; INFLUENZA B VIRUS;

ANALYSIS OF VARIANCE; ANIMALS; AREA UNDER CURVE; DNA PRIMERS; DOGS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; GENETIC FITNESS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INFLUENZA B VIRUS; KINETICS; MADIN DARBY CANINE KIDNEY CELLS; MUTATION, MISSENSE; NEURAMINIDASE; OSELTAMIVIR; RESPIRATORY MUCOSA; REVERSE GENETICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ZANAMIVIR;

EID: 84925438631     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02473-14     Document Type: Article

References (80)

1. McCullers JA, Hayden FG. 2012. Fatal influenza B infections: time to reexamine influenza research priorities. J Infect Dis 205:870-872. http://dx.doi.org/10.1093/infdis/jir865.
2. Gutierrez-Pizarraya A, Perez-Romero P, Alvarez R, Aydillo TA, Osorio-Gomez G, Milara-Ibanez C, Sanchez M, Pachon J, Cordero E. 2012. Unexpected severity of cases of influenza B infection in patients that required hospitalization during the first postpandemic wave. J Infect 65: 423-430. http://dx.doi.org/10.1016/j.jinf.2012.07.004.
3. Paddock CD, Liu L, Denison AM, Bartlett JH, Holman RC, Deleon-Carnes M, Emery SL, Drew CP, Shieh WJ, Uyeki TM, Zaki SR. 2012. Myocardial injury and bacterial pneumonia contribute to the pathogenesis of fatal influenza B virus infection. J Infect Dis 205:895-905. http://dx.doi.org/10.1093/infdis/jir861.
4. Aebi T, Weisser M, Bucher E, Hirsch HH, Marsch S, Siegemund M. 2010. Co-infection of influenza B and streptococci causing severe pneumonia and septic shock in healthy women. BMC Infect Dis 10:308. http://dx.doi.org/10.1186/1471-2334-10-308.
5. Chen SH, Huang IA, Wu CT, Hsia SH, Hung PC, Chiu CH. 2011. Complicated features in a young child with influenza B virus pneumonia and co-infection with Stenotrophomonas maltophilia. Ann Trop Paediatr 31:159-162. http://dx.doi.org/10.1179/1465328111Y.0000000012.
6. Yusuf K, Soraisham AS, Fonseca K. 2007. Fatal influenza B virus pneumonia in a preterm neonate: case report and review of the literature. J Perinatol 27:623-625. http://dx.doi.org/10.1038/sj.jp.7211802.
7. Goenka A, Michael BD, Ledger E, Hart IJ, Absoud M, Chow G, Lilleker J, Lunn M, McKee D, Peake D, Pysden K, Roberts M, Carrol ED, Lim M, Avula S, Solomon T, Kneen R. 2014. Neurological manifestations of influenza infection in children and adults: results of a national British surveillance study. Clin Infect Dis 58:775-784. http://dx.doi.org/10.1093/cid/cit922.
8. Barr IG, Jelley LL. 2012. The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs 72:2177-2185. http://dx.doi.org/10.2165/11641110-000000000-00000.
9. Ambrose CS, Levin MJ. 2012. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother 8:81-88. http://dx.doi.org/10.4161/hv.8.1.17623.
10. FDA. 2014. FDA approves rapivab to treat flu infection. FDA, Rockville, MD. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htm. Accessed 28 December 2014.
11. Nguyen HT, Fry AM, Gubareva LV. 2012. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antivir Ther 17:159-173. http://dx.doi.org/10.3851/IMP2067.
12. Burnham AJ, Baranovich T, Govorkova EA. 2013. Neuraminidase inhibitors for influenza B virus infection: efficacy and resistance. Antiviral Res 100:520-534. http://dx.doi.org/10.1016/j.antiviral.2013.08.023.
13. Oakley AJ, Barrett S, Peat TS, Newman J, Streltsov VA, Waddington L, Saito T, Tashiro M, McKimm-Breschkin JL. 2010. Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses. J Med Chem 53:6421-6431. http://dx.doi.org/10.1021/jm100621s.
14. McKimm-Breschkin JL. 2000. Resistance of influenza viruses to neuraminidase inhibitors-a review. Antiviral Res 47:1-17. http://dx.doi.org/10.1016/S0166-3542(00)00103-0.
15. Okomo-Adhiambo M, Sleeman K, Lysen C, Nguyen HT, Xu X, Li Y, Klimov AI, Gubareva LV. 2013. Neuraminidase inhibitor susceptibility surveillance of influenza viruses circulating worldwide during the 2011 Southern Hemisphere season. Influenza Other Respir Viruses 7:645-658. http://dx.doi.org/10.1111/irv.12113.
16. Fujisaki S, Takashita E, Yokoyama M, Taniwaki T, Xu H, Kishida N, Sato H, Tashiro M, Imai M, Odagiri T. 2012. A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs. Biochem Biophys Res Commun 429:51-56. http://dx.doi.org/10.1016/j.bbrc.2012.10.095.
17. WHO. 2012. WHO information for molecular diagnosis of influenza virus in humans-update. WHO, Geneva, Switzerland. http://www.who.int/influenza/gisrs_laboratory/molecular_diagnosis/en/. Accessed 28 December 2014.
18. Domingo E, Menendez-Arias L, Holland JJ. 1997. RNA virus fitness. Rev Med Virol 7:87-96. http://dx.doi.org/10.1002/(SICI)1099-1654(199707)7 :2<87::AID-RMV188>3.0.CO;2-0.
19. Kelso A, Hurt AC. 2012. The ongoing battle against influenza: drugresistant influenza viruses: why fitness matters. Nat Med 18:1470-1471. http://dx.doi.org/10.1038/nm.2954.
20. Garg S, Moore Z, Lee N, McKenna J, Bishop A, Fleischauer A, Springs CB, Nguyen HT, Sheu TG, Sleeman K, Finelli L, Gubareva L, Fry AM. 2013. A cluster of patients infected with I221V influenza B virus variants with reduced oseltamivir susceptibility-North Carolina and South Carolina, 2010-2011. J Infect Dis 207:966-973. http://dx.doi.org/10.1093/infdis/jis776.
21. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, Kimura K, Kiso M, Shimizu H, Kawakami C, Koike K, Mitamura K, Kawaoka Y. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442. http://dx.doi.org/10.1001/jama.297.13.1435.
22. Sleeman K, Sheu TG, Moore Z, Kilpatrick S, Garg S, Fry AM, Gubareva LV. 2011. Influenza B viruses with mutation in the neuraminidase active site, North Carolina, USA, 2010-11. Emerg Infect Dis 17:2043-2046. http://dx.doi.org/10.3201/eid1711.110787.
23. Wang D, Sleeman K, Huang W, Nguyen HT, Levine M, Cheng Y, Li X, Tan M, Xing X, Xu X, Klimov AI, Gubareva LV, Shu Y. 2013. Neuraminidase inhibitor susceptibility testing of influenza type B viruses in China during 2010 and 2011 identifies viruses with reduced susceptibility to oseltamivir and zanamivir. Antiviral Res 97:240-244. http://dx.doi.org/10.1016/j.antiviral.2012.12.013.
24. Belser JA, Katz JM, Tumpey TM. 2011. The ferret as a model organism to study influenza A virus infection. Dis Model Mech 4:575-579. http://dx.doi.org/10.1242/dmm.007823.
25. Huang SS, Banner D, Paquette SG, Leon AJ, Kelvin AA, Kelvin DJ. 2014. Pathogenic influenza B virus in the ferret model establishes lower respiratory tract infection. J Gen Virol 95(Pt 10):2127-2139. http://dx.doi.org/10.1099/vir.0.064352-0.
26. Kim YH, Kim HS, Cho SH, Seo SH. 2009. Influenza B virus causes milder pathogenesis and weaker inflammatory responses in ferrets than influenza A virus. Viral Immunol 22:423-430. http://dx.doi.org/10.1089/vim.2009.0045.
27. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG. 1998. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 178:1257-1262. http://dx.doi.org/10.1086/314440.
28. Mishin VP, Hayden FG, Gubareva LV. 2005. Susceptibilities of antiviralresistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 49:4515-4520. http://dx.doi.org/10.1128/AAC.49.11.4515-4520.2005.
29. Pica N, Chou YY, Bouvier NM, Palese P. 2012. Transmission of influenza B viruses in the guinea pig. J Virol 86:4279-4287. http://dx.doi.org/10.1128/JVI.06645-11.
30. Lai C, Struckhoff JJ, Schneider J, Martinez-Sobrido L, Wolff T, Garcia-Sastre A, Zhang DE, Lenschow DJ. 2009. Mice lacking the ISG15 E1 enzyme UbE1L demonstrate increased susceptibility to both mouseadapted and non-mouse-adapted influenza B virus infection. J Virol 83: 1147-1151. http://dx.doi.org/10.1128/JVI.00105-08.
31. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, Wolff T, Osiak A, Levine B, Schmidt RE, Garcia-Sastre A, Leib DA, Pekosz A, Knobeloch KP, Horak I, Virgin HW, IV. 2007. IFNstimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A 104:1371-1376. http://dx.doi.org/10.1073/pnas.0607038104.
32. Fabian P, McDevitt JJ, DeHaan WH, Fung RO, Cowling BJ, Chan KH, Leung GM, Milton DK. 2008. Influenza virus in human exhaled breath: an observational study. PLoS One 3:e2691. http://dx.doi.org/10.1371/journal.pone.0002691.
33. Lin H, Li H, Cho HJ, Bian S, Roh HJ, Lee MK, Kim JS, Chung SJ, Shim CK, Kim DD. 2007. Air-liquid interface (ALI) culture of human bronchial epithelial cell monolayers as an in vitro model for airway drug transport studies. J Pharm Sci 96:341-350. http://dx.doi.org/10.1002/jps.20803.
34. Roy CJ, Milton DK. 2004. Airborne transmission of communicable infection- the elusive pathway. N Engl J Med 350:1710-1712. http://dx.doi.org/10.1056/NEJMp048051.
35. Burnham AJ, Baranovich T, Marathe BM, Armstrong J, Webster RG, Govorkova EA. 2014. Fitness costs for influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother 58:2718-2730. http://dx.doi.org/10.1128/AAC.02628-13.
36. Ilyushina NA, Govorkova EA, Gray TE, Bovin NV, Webster RG. 2008. Human-like receptor specificity does not affect the neuraminidaseinhibitor susceptibility of H5N1 influenza viruses. PLoS Pathog 4:e1000043. http://dx.doi.org/10.1371/journal.ppat.1000043.
37. Thompson CI, Barclay WS, Zambon MC, Pickles RJ. 2006. Infection of human airway epithelium by human and avian strains of influenzaAvirus. J Virol 80:8060-8068. http://dx.doi.org/10.1128/JVI.00384-06.
38. Hoffmann E, Mahmood K, Yang CF, Webster RG, Greenberg HB, Kemble G. 2002. Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci U S A 99:11411-11416. http://dx.doi.org/10.1073/pnas.172393399.
39. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am J Hyg 27:493-497.
40. Potier M, Mameli L, Belisle M, Dallaire L, Melancon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha-D-N-acetylneuraminate) substrate. Anal Biochem 94:287-296. http://dx.doi.org/10.1016/0003-2697(79)90362-2.
41. Marathe BM, Leveque V, Klumpp K, Webster RG, Govorkova EA. 2013. Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrate. PLoS One 8:e71401. http://dx.doi.org/10.1371/journal.pone.0071401.
42. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ. 2003. High-resolution genotyping by amplicon melting analysis using LCGreen. Clin Chem 49:853-860. http://dx.doi.org/10.1373/49.6.853.
43. Marshall N, Priyamvada L, Ende Z, Steel J, Lowen AC. 2013. Influenza virus reassortment occurs with high frequency in the absence of segment mismatch. PLoS Pathog 9:e1003421. http://dx.doi.org/10.1371/journal.ppat.1003421.
44. Maree AF, Keulen W, Boucher CA, De Boer RJ. 2000. Estimating relative fitness in viral competition experiments. J Virol 74:11067-11072. http://dx.doi.org/10.1128/JVI.74.23.11067-11072.2000.
45. Holland JJ, de la Torre JC, Clarke DK, Duarte E. 1991. Quantitation of relative fitness and great adaptability of clonal populations of RNA viruses. J Virol 65:2960-2967.
46. Heldt FS, Frensing T, Pflugmacher A, Gropler R, Peschel B, Reichl U. 2013. Multiscale modeling of influenza A virus infection supports the development of direct-acting antivirals. PLoS Comput Biol 9:e1003372. http://dx.doi.org/10.1371/journal.pcbi.1003372.
47. WHO. 2013. Meeting of the WHO expert working group on surveillance of influenza antiviral susceptibility, Geneva, July 2013. Wkly Epidemiol Rec 88:477-482.
48. WHO. 2012. Laboratory methodologies for testing the antiviral susceptibility of influenza viruses: neuraminidase inhibitor (NAI).WHO, Geneva, Switzerland. www.who.int/influenza/gisrs_laboratory/antiviral_susceptibility/nai _overview/en/index.html. Accessed 28 December 2014.
49. Pozo F, Lina B, Andrade HR, Enouf V, Kossyvakis A, Broberg E, Daniels R, Lackenby A, Meijer A, Community Network of Reference Laboratories for Human Influenza in Europe. 2013. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. J Clin Virol 57:5-12. http://dx.doi.org/10.1016/j.jcv.2013.01.009.
50. Marcus PI, Ngunjiri JM, Sekellick MJ. 2009. Dynamics of biologically active subpopulations of influenza virus: plaque-forming, noninfectious cell-killing, and defective interfering particles. J Virol 83:8122-8130. http://dx.doi.org/10.1128/JVI.02680-08.
51. Nayak DP, Chambers TM, Akkina RK. 1985. Defective-interfering (DI) RNAs of influenza viruses: origin, structure, expression, and interference. Curr Top Microbiol Immunol 114:103-151.
52. Saira K, Lin X, DePasse JV, Halpin R, Twaddle A, Stockwell T, Angus B, Cozzi-Lepri A, Delfino M, Dugan V, Dwyer DE, Freiberg M, Horban A, Losso M, Lynfield R, Wentworth DN, Holmes EC, Davey R, Wentworth DE, Ghedin E. 2013. Sequence analysis of in vivo defective interfering-like RNA of influenza A H1N1 pandemic virus. J Virol 87:8064-8074. http://dx.doi.org/10.1128/JVI.00240-13.
53. Escuret V, Frobert E, Bouscambert-Duchamp M, Sabatier M, Grog I, Valette M, Lina B, Morfin F, Ferraris O. 2008. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors. J Clin Virol 41:25-28. http://dx.doi.org/10.1016/j.jcv.2007.10.019.
54. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M. 2006. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 50:2395-2402. http://dx.doi.org/10.1128/AAC.01339-05.
55. Hurt AC, Barr IG, Hartel G, Hampson AW. 2004. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir. Antiviral Res 62:37-45. http://dx.doi.org/10.1016/j.antiviral.2003.11.008.
56. Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV. 2010. Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective. Viruses 2:2269-2289. http://dx.doi.org/10.3390/v2102269.
57. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten RJ, Xu X, Bright RA, Butler EN, Wallis TR, Klimov AI, Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52:3284-3292. http://dx.doi.org/10.1128/AAC.00555-08.
58. Neuraminidase Inhibitor Susceptibility Network. 2007. Monitoring of neuraminidase inhibitor resistance among clinical influenza virus isolates in Japan during the 2003-2006 influenza seasons. Wkly Epidemiol Rec 82:149-150.
59. Tashiro M, McKimm-Breschkin JL, Saito T, Klimov A, Macken C, Zambon M, Hayden FG, Neuraminidase Inhibitor Susceptibility Network. 2009. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007. Antivir Ther 14:751-761. http://dx.doi.org/10.3851/IMP1194.
60. Jackson D, Barclay W, Zurcher T. 2005. Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 55:162-169. http://dx.doi.org/10.1093/jac/dkh528.
61. Staschke KA, Colacino JM, Baxter AJ, Air GM, Bansal A, Hornback WJ, Munroe JE, Laver WG. 1995. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 214:642-646. http://dx.doi.org/10.1006/viro.1995.0078.
62. Barnett JM, Cadman A, Burrell FM, Madar SH, Lewis AP, Tisdale M, Bethell R. 1999. In vitro selection and characterisation of influenza B/Beijing/1/87 isolates with altered susceptibility to zanamivir. Virology 265: 286-295. http://dx.doi.org/10.1006/viro.1999.0058.
63. Cheam AL, Barr IG, Hampson AW, Mosse J, Hurt AC. 2004. In vitro generation and characterisation of an influenza B variant with reduced sensitivity to neuraminidase inhibitors. Antiviral Res 63:177-181. http://dx.doi.org/10.1016/j.antiviral.2004.04.004.
64. Sheu TG, Deyde VM, Garten RJ, Klimov AI, Gubareva LV. 2010. Detection of antiviral resistance and genetic lineage markers in influenza B virus neuraminidase using pyrosequencing. Antiviral Res 85:354-360. http://dx.doi.org/10.1016/j.antiviral.2009.10.022.
65. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. 1997. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 71:3385-3390.
66. Sleeman K, Guo Z, Barnes J, Shaw M, Stevens J, Gubareva LV. 2013. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis 19:1521-1524. http://dx.doi.org/10.3201/eid1909.130724.
67. Wang Q, Cheng F, Lu M, Tian X, Ma J. 2008. Crystal structure of unliganded influenza B virus hemagglutinin. J Virol 82:3011-3020. http://dx.doi.org/10.1128/JVI.02477-07.
68. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, Van Phan T, Smythe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, Penn CR. 1993. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 363:418-423. http://dx.doi.org/10.1038/363418a0.
69. Higgins RR, Beniprashad M, Chong-King E, Li Y, Bastien N, Low DE, Gubbay JB. 2012. Recovery of influenza B virus with the H273Y point mutation in the neuraminidase active site from a human patient. J Clin Microbiol 50:2500-2502. http://dx.doi.org/10.1128/JCM.00682-12.
70. Ilyushina NA, Seiler JP, Rehg JE, Webster RG, Govorkova EA. 2010. Effect of neuraminidase inhibitor-resistant mutations on pathogenicity of clade 2.2 A/Turkey/15/06 (H5N1) influenza virus in ferrets. PLoS Pathog 6:e1000933. http://dx.doi.org/10.1371/journal.ppat.1000933.
71. Duan S, Boltz DA, Seiler P, Li J, Bragstad K, Nielsen LP, Webby RJ, Webster RG, Govorkova EA. 2010. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 6:e1001022. http://dx.doi.org/10.1371/journal.ppat.1001022.
72. Ives JA, Carr JA, Mendel DB, Tai CY, Lambkin R, Kelly L, Oxford JS, Hayden FG, Roberts NA. 2002. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 55:307-317. http://dx.doi.org/10.1016/S0166-3542(02)00053-0.
73. Moscona A. 2009. Global transmission of oseltamivir-resistant influenza. N Engl J Med 360:953-956. http://dx.doi.org/10.1056/NEJMp0900648.
74. Bloom JD, Gong LI, Baltimore D. 2010. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328: 1272-1275. http://dx.doi.org/10.1126/science.1187816.
75. Rameix-Welti MA, Munier S, Le Gal S, Cuvelier F, Agou F, Enouf V, Naffakh N, van der Werf S. 2011. Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution. Antivir Ther 16:597-603. http://dx.doi.org/10.3851/IMP1804.
76. Hurt AC, Hardie K, Wilson NJ, Deng YM, Osbourn M, Leang SK, Lee RT, Iannello P, Gehrig N, Shaw R, Wark P, Caldwell N, Givney RC, Xue L, Maurer-Stroh S, Dwyer DE, Wang B, Smith DW, Levy A, Booy R, Dixit R, Merritt T, Kelso A, Dalton C, Durrheim D, Barr IG. 2012. Characteristics of a widespread community cluster of H275Y oseltamivirresistant A(H1N1)pdm09 influenza in Australia. J Infect Dis 206:148-157. http://dx.doi.org/10.1093/infdis/jis337.
77. Butler J, Hooper KA, Petrie S, Lee R, Maurer-Stroh S, Reh L, Guarnaccia T, Baas C, Xue L, Vitesnik S, Leang SK, McVernon J, Kelso A, Barr IG, McCaw JM, Bloom JD, Hurt AC. 2014. Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog 10: e1004065. http://dx.doi.org/10.1371/journal.ppat.1004065.
78. Pinilla LT, Holder BP, Abed Y, Boivin G, Beauchemin CA. 2012. The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets. J Virol 86:10651-10660. http://dx.doi.org/10.1128/JVI.07244-11.
79. Smith AM, Perelson AS. 2011. Influenza A virus infection kinetics: quantitative data and models. Wiley Interdiscip Rev Syst Biol Med 3:429-445. http://dx.doi.org/10.1002/wsbm.129.
80. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. 2004. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78:12665-12667. http://dx.doi.org/10.1128/JVI.78.22.12665-12667.2004.